| Literature DB >> 17919325 |
Alexander Albert1, Ines Florath, Ulrich Rosendahl, Wael Hassanein, Eberhard V Hodenberg, Stefan Bauer, Ina Ennker, Jürgen Ennker.
Abstract
BACKGROUND: The implantation of stentless valves is technically demanding and the outcome may depend on the performance of surgeons. We studied systematically the role of surgeons and other possible determinants for mid-term survival, postoperative gradients and Quality of Life (QoL) after aortic valve replacement (AVR) with Freestyle stentless bioprostheses.Entities:
Mesh:
Year: 2007 PMID: 17919325 PMCID: PMC2146998 DOI: 10.1186/1749-8090-2-40
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Figure 1Survivor functions for patients after AVR compared to the age- and gender matched German population. The actuarial survival rate at 6 years was 61.4 ± 3.8 % and comparable to the estimated survival function for 75 year-old male and female Germans.
Figure 2Mean scores of the six NHP sections compared to the age- and gender-matched general German population. The QoL after AVR with the stentless bioprosthesis over the follow-up time was compared to the general German population of the same age and gender. Besides from the section "pain" the patients after AVR showed no significant differences to the normal population. Our observation that the patients after AVR have lower values for pain may be explained by misunderstanding of the questionnaires: the patients thought that the question asking for pain mean only cardiac related pain, whereas in the general population all other kinds of pain were included.
Predictors of 30-day- and 6-months-mortality and survival time. Apparently valve size is a risk factor in the first step of the analysis. However, after adjustment for gender, age, BSA, BMI and body size, valve size disappeared (p < 0.05)
| Myocardial decompensation | 2.9 | 1.1–7.2 | ||||
| Diabetes mellitus | 2.7 | 1.3–5.5 | 2.0 | 1.3–3.0 | ||
| Atrial fibrillation | 2.3 | 1.1–5.2 | 2.8 | 1.8–4.4 | ||
| Peripheral vascular disease | 2.2 | 1.2–4.0 | ||||
| Antithrombine III (%) | 0.97 | 0.94–0.99 | 0.96 | 0.94–0.99 | ||
| Urea concentration (mg/dl) | 1.02 | 1.01–1.03 | 1.02 | 1.011.02 | ||
| Valve size | ||||||
| Female and age > 74 years | 4.0 | 1.4–11.0 | ||||
| BSA < 1.78 m2 | 3.0 | 1.51–6.07 | ||||
| Female and age > 80 years | 1.8 | 1.03–2.94 | ||||
| BMI < 24 and body size < 165 cm | 1.7 | 1.02–2.93 | ||||
CI = Confidential Interval
HR = Hazard Ratio
OR = Odds Ratio
p = p-value of model improvement
Significant predictors of impaired QoL are listed
| Risk factors | Energy [OR;95%CI] | Pain [OR;95%CI] | Emotional reaction [OR;95%CI] | Sleep [OR;95%CI] | Social isolation [OR;95%CI] | Physical mobility [OR;95%CI] |
| Age | 1.1; 1.0–1.1 | (> 76), 2.8; 1.7–4.9 | (> 79), 2.6; 1.4–4.8 | 1.1; 05–1.2 | (> 70), 5.6; 1.9–16.7), | 1.1; 1.08–1.2 |
| Female gender | 2.2; 1.4–3.6 | 2.3; 1.4–3.9 | 2.9; 1.6–5.7 | 2.7; 1.6–4.3 | ||
| Lower potassium 1 | 0.4; 0.2–0.7 | |||||
| Higher creatinine 2 | 2.7; 1.3–5.7 | |||||
| BMI 3 | 1.1; 1.0–1.2 | 1.0; 1.0–1.1 | ||||
| History of syncope | 2.1; 1.0–4.1 | |||||
| Advanced NYHAclass | 2.3; 1.4–4.0 | 2.0; 1.2–3.3 | 1.7; 1.1–2.8 | |||
| Lower hemoglobine | (< 13) 2.0; 1.2–3.5 | |||||
| History of MI 4 | 3.2; 1.3–7.5 | |||||
| COPD 5 | 2.6; 1.3–5.3 | |||||
| Previous CABG | 6.2; 4.5–7.9 | |||||
| De Ritis-ratio (AST/ALT) 6 | 1.6; 1.1–2.4 | |||||
| Neurological disorders | 2.2; 1.0–4.8 | 3.7; 1.5–8.7 | ||||
| Concomitant CABG | 1.7; 1.01–2.8 | |||||
| Higher urea7 | 1.01; 1.0–1.04 | |||||
| Non-elective procedure | 2.5; 1.4–4.7 | |||||
| Pacemaker before AVR | 10.5; 1.1–99.6 | |||||
| Mean gradients (1 mmHg) | 1.1; 1.0–1.1 |
Abbrevations: 1: potassium concentration (mmol/l); lower potassium probably as marker for diuretic therapy, 2: creatinine concentration (mg/dl), 3: body mass index, 4: Myocardial infarction, 5: Chronic obstructive pulmonary disease, 6 De ritis ratio: De ritis-ratio as marker for liver damage, e.g. ethanol intake 7 Urea concentration (mg/dl),
Mean and maximum transvalvular pressure gradients (mmHg) at discharge (5 to 7 days after AVR)
| Subcoronary implantation | Total root replacement | |||||||
| Valve size | Mean | N | Max | N | Mean | N | Max | N |
| 19 | 29.8 ± 14.4 | 9 | 54.2 ± 23.2 | 9 | - | 0 | - | 0 |
| 21 | 22.0 ± 8.9 | 127 | 40.4 ± 14.5 | 119 | 13.7 ± 4.2 | 3 | 25.7 ± 7.5 | 3 |
| 23 | 19.6 ± 7.6 | 176 | 35.5 ± 12.8 | 149 | 13.5 ± 6.0 | 27 | 25.3 ± 10.1 | 26 |
| 25 | 17.0 ± 6.9 | 100 | 31.0 ± 14.9 | 80 | 10.8 ± 5.0 | 20 | 19.8 ± 10.9 | 19 |
| 27 | 14.8 ± 5.7 | 50 | 26.7 ± 9.4 | 47 | 7.2 ± 2.0 | 9 | 13.2 ± 4.3 | 9 |
Saturated propensity score predicting a mean transvalvular gradient after AVR > 20 mmHg
| Predictors | Odds ratio | 95% CI |
| Male gender | 1.83 | 1–3.36 |
| Body height (cm) | 0.98 | 0.93–0.99 |
| Subcoronary implantation technique | 11.4 | 2.59–49.9 |
| Indexed geometric orifice area | 0.12 | 0.05–0.28 |
| Less-experienced surgeon | 3.64 | 2.34–5–66 |
| Ejection fraction (%?) | 1.01 | 1–1.03 |
| Preoperative maximum transvalvular gradient (mmHg) | 1.01 | 0.99–1.02 |
| White blood cell count (cells*1000/μl) | 1.11 | 1.02–1.22 |
| Total serum protein (g/dl) | 0.55 | 0.4–0.77 |
| Glutamic-oxalacetic transaminase (U/l) | 0.97 | 0.93–0.99 |
| Potassium (mmol/l) | 0.48 | 0.29–0.78 |
| Mean corpuscular volume (fl) | 1.04 | 0.99–1.08 |
| Atrial fibrillation | 0.6 | 0.3–1.2 |
| Chronic pulmonary disease | 1.5 | 0.81–2.75 |
| Renal insufficiency | 1.41 | 0.82–2.41 |
| Peripheral occlusive arterial disease | 0.56 | 0.2–1.56 |
CI – confidential interval
Figure 3Risk factors for higher transvalvular gradients after stentless valve implantation. By solving the multivariate equations we had illuminated the importance of the dominant risk factors for higher gradients after stentless valve implantation: valve size in relation to BSA (IGOE), subcoronary technique, preoperative gradients, and the surgeons C, D, E. Other risk factors (cardiac, haematological) were less important (se table 4). With total root technique virtually no increase of the risk for higher gradients with decreasing IGOA was observed, whereas with subcoronary technique the risk increases exponentially.
Experience of the surgeons at end of 2004
| Years in Cardiac Surgery | Major cardiac surgery performed [N] | Valve implantation performed [N] | Freestyle valve implantation performed [N] | Mean transprosthetic gradients in subcoronary technique (ANOVA, p < 0.001) | |
| F | > 20 | > 5000 | > 1000 | 26 | 14 |
| E | > 10 | 2500 | 400 | 66 | 17 |
| C | > 20 | > 4000 | > 1000 | 280 | 18 |
| A | > 10 | 2000 | 400 | 53 | 22 |
| B | > 15 | 2500 | 500 | 74 | 22 |
| D | > 10 | 1000 | 250 | 41 | 24 |
Mean transvalvular gradients for the main valve sizes by surgeon
| Valve Size | |||||||
| 21 mm | 23 mm | 25 mm | |||||
| Surgeons | N cases | ||||||
| Trainees | 43 | 19 ± 2.4 | 0 | 16 ± 1.8 | .- | 17 ± 2.3 | .- |
| A | 53 | 24 ± 2.3 | 20 | 22 ± 1.7 | 24 | 16 ± 2.3 | 22 |
| B | 74 | 25 ± 1.9 | 27 | 21 ± 1.3 | 35 | 19 ± 1.8 | 28 |
| C | 280 | 21 ± 1.1 | 40 | 18 ± 0.8 | 27 | 16 ± 0.9 | 28,4 |
| D | 41 | 23 ± 2.7 | 38 | 26 ± 1.7 | 35 | 19 ± 2.8 | 35 |
| E | 67 | 20 ± 1.9 | 25 | 17 ± 1.4 | 30 | 13 ± 1.7 | 16 |
| F | 28 | 10 ± 8.2 | 27 | 12 ± 2.0 | 19 | 12 ± 2.6 | 18 |
| ANOVA | P = 0.1 | p < 0.001 | P = 0.1 | ||||
Figure 4Learning curve of one surgeon concerning transprosthetic gradients after stentless valve implantation [p < 0.001]. The example of one surgeon shows that the mean gradients in subcoronary technique decrease during a time period of 8 years. Beside proper valve sizing and use of total root technique in difficult cases with small aortic roots, the phenomena can be best explained by the increasing ability of the surgeon to fit the valve smoothly into the aortic root and to handle the various aortic root geometries.